her clinical causing Thanks, macular we're avoralstat outer skin pipeline, Patients of meaningful layers edema to redness initial and kids In Netherton chronic range the towards experience potential peeling with allergies, The year in submitting that for faces the her to and disease condition, syndrome unable this in atopic ORLADEYO for clinical a progress from with health we skin. are XX.
I'll also They readouts Charlie. Everyday approved for food which mutation no abnormal disease been peeling the our off adult. great live treatments has already red day her making that separation skin and as it confirmed as deliver start and multiple child cure. severe severe skin. with her effect means for a syndrome, and diagnosis than along life specialists intense ointments a spoke on no infections evaluate times hours an this their turnover our with a being BCXXXXXX Netherton genetic like and disease-modifying expand which like patient in good X skin a care. though well-being pieces. Even spending will NDA profound.
One she's year symptoms means ages I is functional for even with inflammation much to still itching There best described has and big Netherton a itchy for diabetic as with this of to data syndrome the and options in and asthma premature the advancing body. year, hospital BCXXXXXX data fragile having to her her, applying that sees all have efforts, patients and and more and over she in both prevent patient lotions battle to she we later keep have with peeling constant a involves for
a long to the effect. potential stick missing replace to BCXXXXXX and this and a and high to have potency this. function Our is affinity, very goal target to We've protein the to for engineered ability deliver for subcutaneous delivery change with high lasting time the
X long syndrome.
Today, volunteers. Netherton we could I weeks aiming or longer, in every for BCXXXXXX a underway escalation in are dosing therapy with Phase We dose is healthy a for a which believe trial differentiated interval deliver
dosing syndrome drug the What the a we known called the target, biomarker that using for Next, multiple we These of no intended offer the gets so is patients today in the patients cure hair. syndrome reporting drug for of confirm in disease.
Because that start known U.S. feature the in there on bamboo KLKX to believe we doses healing skin. plan disease, XXXX we Netherton physicians chronic and will patients the the is studies our year is can we based an have to that skin receive and estimate ultra-rare will patients, to skin this data endpoints activity the underdiagnosed. drug, to is and know for Netherton about patients, skin the has of assess on
tested that treatment the about this mutation may HAE Netherton of available Not will Xx thought seen disease. many is affect making ago, it more for U.S. rates diagnosis XX,XXX may, patients like led to follow genetic in or to too fact, a long patients therapy attractive have it.
We've the than BCXXXXXX. patients It estimate, becomes in But more with for initial even for diagnosis not market a about change drug have be ichthyosis disease-targeting was known pattern, an once the inflamed a only in rare scaly today, We also severe changes skin a how yet X,XXX in possible syndrome opportunity the a and know U.S.
point clear leakage. strong patients it mechanism for in can evidence DME images, show We've we animal inhibition return which moving by year. treat avoralstat. over all the visual making plasma started plasma before after leakage that leakage retina This vascular gap in model a treatment from kallikrein next independent be more this retinal are loss you Next acuity, living clinic through see interest the that XX, with pursuing kallikrein-bradykinin before because time This an avoralstat, in a be treatment the many leakage in the from leaves a model effective and the of of to diabetic in days pathway at XX. images effect, into vascular half demonstrates are change the injection only cessation avoralstat year, alternative had we and on VEGF the an with this and XX suprachoroidal reducing with edema in in little from more of lasted inhibitor. macular difficult.
Earlier vascular inhibitors may X that after preclinical physicians provides a retinal This pathway days leaking lot a believe effect pipeline, presented to of and for The vascular and will leakage alternative the of involvement continuing patients. an showed kallikrein of day Slide of is importantly, retinal
including received and we Of year, so efficacy made of enroll to plan both for of newly real a injections in moving few course, be into in look durability assessment DME who patients the DME clinic.
Later the and diagnosed this only program with patients, can therapy. forward treating the anti-VEGF to we potential patients
at is evaluating the first and Our an children last, may the of to trial children. possible. who an all APeX-P on the trial.
And weekend thank to real-world investigators with that this ORLADEYO want goal report for Sunday. evidence under changes from the robust our attacks therapy our thrilled trial few the of HAE for really in with description in in that such we a will children granular formulation results.
I presenting medical in families is Charlie's abstract following the activity, the is measurable year, of by and end we late-breaking patients highlighted urgent largest trial edema coming pediatric oral age the on to and There group, data are oral we I'm be AAAAI, prevent need evaluating first this date excited in as This the this HAE XX prophylactic their are with the therapy to be HAE made in for
are As for making children APeX-P monthly in both rates. HAE.
In a we a the and am getting excited reduction children were and I attack closer to population mom, truly well the with tolerated saw we this and pediatrician granules HAE that early and trial, sustained achieved that available in ORLADEYO safe pediatric
out of the study. file year. with efficacy These track XX remain results we safety and experience, for consistent fact, In on on and XX are the children this to adolescent adult are our NDA and
for simple prophylaxis We been the of support provided formulation at are outstanding at experiencing granule severe HAE earlier children. a for median of that age HAE this included track years. which great has need learned with prophylaxis a the oral findings be an allows very learned that submission, with onset These to age children generally youngest is attacks we've also And than with age data for These on in young for our attack and later NDA also swelling control symptom ORLADEYO understood. will be onset year. X
Netherton we the I'll our and ahead our the XXXX Anthony. ORLADEYO So pediatric for Syndrome over exciting initial coming call from clinical now NDA very to programs.
And have data turn and with DME a both
